| abstract |
The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to OX40, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine. |